カテゴリ： GlobalData, アメリカ, 企業調査

Charles River Laboratories International Inc (CRL)-製薬・医療分野：企業M&A・提携分析

◆英語タイトル：Charles River Laboratories International Inc (CRL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA8012223
◆発行会社（調査会社）：GlobalData
◆発行日：2017年12月14日
◆ページ数：95
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Charles River Laboratories International Inc (Charles River) is a contract research organization (CRO) that provides essential products and services to accelerate the research, drug discovery and development. It offers various basic research, drug discovery and safety assessment services. The organization also offers clinical support, manufacturing support and operations and staffing support. It focuses on providing solutions targeted against therapeutic areas of cardiovascular, central nervous system, metabolic inflammation, oncology, ophthalmology, respiratory disease and musculoskeletal disease. Charles River caters its products and services to global pharmaceutical companies, biotechnology companies, government agencies, as well as leading hospitals and academic institutions, and operates through a network facilities located worldwide. Charles River is headquartered in Wilmington, Massachusetts, the US.

Charles River Laboratories International Inc (CRL) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 6
Charles River Laboratories International Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Charles River Laboratories International Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Charles River Laboratories International Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Charles River Laboratories International Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 10
Charles River Laboratories International Inc, Medical Devices Deals, 2011 to YTD 2017 11
Charles River Laboratories International Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
Charles River Laboratories International Inc, Pharmaceuticals & Healthcare, Deal Details 16
Asset Purchase 16
WIL Research Acquires Pharma Services Business Of Ricerca Biosciences 16
Partnerships 18
Inscopix Enters into Partnership with Brains On-Line 18
Nimbus Therapeutics Enters into Agreement with Charles River Laboratories International 19
Charles River Laboratories International Expands its Agreement with Chiesi Farmaceutici 20
Charles River Laboratories International Extends Agreement with Genentech 21
Charles River Labs Enters into Agreement with Tri-Institutional Therapeutics Discovery Institute 22
Moderna Therapeutics Enters into Agreement with Charles River Labs 23
Charles River Labs Enters into Agreement with BioMotiv 24
Eisai Extends Research Agreement with Charles River Labs 25
Charles River Labs Expands its Agreement with Michael J. Fox Foundation for Parkinson’s Research 26
Charles River Labs Enters into Agreement with Antabio 27
Charles River Labs Enters into Agreement with Pcovery 28
Charles River Labs Enters into Agreement with British Columbia Cancer Agency 29
Charles River Lab Extends Co-Development Agreement with CHDI Foundation 30
BioFocus Enters Into Drug Discovery Agreement With Boehringer Ingelheim 31
BioFocus Extends Agreement With Michael J. Fox Foundation For Parkinson’s Disease 32
Applied StemCell Enters Into Distribution Agreement With Charles River Labs For Genetically Modified Targatt Mouse 33
BioFocus Enters Into Agreement With ChanTest 34
Charles River Labs Expands its Agreement with AstraZeneca 35
Ono Pharma Enters Into Discovery Agreement With BioFocus For CNS Drugs 36
Activiomics Enters Into Drug Discovery Agreement With BioFocus 37
Ono Pharma Enters Into Drug Discovery Agreement With BioFocus 38
Almirall Enters Into Integrated Drug Discovery Collaboration With BioFocus 39
Protagen Enters Into Co-Marketing Agreement With Charles River Labs 40
BioFocus Enters Into Co-Marketing Agreement With InterMed Discovery 41
BioFocus Enters Into Agreement With Michael J. Fox Foundation For Parkinson’s Disease 42
BioFocus Extends Its Collaboration With Usher III Initiative 43
BioFocus Enters Into Co-Development Agreement With Astellas Pharma 44
BioFocus Enters Into An Agreement With Almac Group 45
ChanTest Corporation Enters Into Co-Marketing Agreement With Molecular Devices 46
Charles River Labs Enters Into Distribution Agreement With Pfizer 47
Ono Pharma Enters Into Co-Development Agreement With BioFocus 48
Licensing Agreements 49
EMD Millipore Enters Into Licensing Agreement With Charles River Labs For TrueSpike Technology 49
Equity Offering 50
Charles River Labs to Invest USD10 Million in BioMotiv 50
Asset Transactions 51
Charles River Labs International Sells Preclinical Assets 51
ShangPharma Acquires Shanghai In-vivo Drug Research Facility From Charles River Labs 52
Acquisition 53
Charles River Laboratories Acquires Brains On-Line 53
Quotient Clinical Acquires QS Pharma from Charles River Labs 54
Charles River Laboratories Acquires Agilux Laboratories for USD64.9 Million 55
Charles River Labs Acquires Blue Stream Labs 56
Charles River Laboratories Acquires WIL Research for USD604.8 Million 57
Charles River Labs Acquires Oncotest 59
Charles River Labs Acquires ChanTest from Ampersand Capital for USD59.2 Million 60
Charles River Labs Completes Acquisition Of BioFocus And Argenta Discovery From Galapagos For USD191.8 Million 61
Charles River Labs Acquires Brass 63
Charles River Labs Completes Acquisition Of 75% Stake In Vital River Labs For US$27 Million 64
Charles River Plans Sale Of The Company 65
Charles River Laboratories International Inc – Key Competitors 66
Charles River Laboratories International Inc – Key Employees 67
Charles River Laboratories International Inc – Locations And Subsidiaries 69
Head Office 69
Other Locations & Subsidiaries 69
Recent Developments 72
Financial Announcements 72
Nov 09, 2017: Charles River Laboratories Announces Third-Quarter 2017 Results from Continuing Operations 72
Aug 09, 2017: Charles River Laboratories Announces Second-Quarter 2017 Results from Continuing Operations 74
May 10, 2017: Charles River Laboratories Announces First-Quarter 2017 Results from Continuing Operations 76
Feb 14, 2017: Charles River Laboratories Announces Fourth-Quarter and Full-Year 2016 Results from Continuing Operations and Provides 2017 Guidance 78
Nov 02, 2016: Charles River Laboratories Announces Third-Quarter 2016 Results from Continuing Operations 81
Aug 03, 2016: Charles River Laboratories Announces Second-Quarter 2016 Results from Continuing Operations 83
May 04, 2016: Charles River Laboratories Announces First-Quarter 2016 Results from Continuing Operations 85
Feb 10, 2016: Charles River Laboratories Announces Fourth-Quarter and Full-Year 2015 Results from Continuing Operations and Provides 2016 Guidance 87
Corporate Communications 90
Jul 05, 2017: Charles River Laboratories Adds Martin Mackay, Ph.D. to Board of Directors 90
Product News 91
Apr 03, 2017: Charles River Laboratories Announces Launch of Triple-Immunodeficient Mouse Model for Oncology Research 91
Other Significant Developments 92
Dec 06, 2017: Charles River Adds ERS License to CRISPR/Cas9 Service Offering 92
May 16, 2017: Charles River Laboratories Announces Updates to Oncology Business 93
Dec 01, 2016: Charles River Laboratories Demonstrates Expertise in CRISPR/Cas9 Genome Engineering Technology 94
Appendix 95
Methodology 95
About GlobalData 95
Contact Us 95
Disclaimer 95

List of Tables
Charles River Laboratories International Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Charles River Laboratories International Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Charles River Laboratories International Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Charles River Laboratories International Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Charles River Laboratories International Inc, Deals By Therapy Area, 2011 to YTD 2017 10
Charles River Laboratories International Inc, Medical Devices Deals, 2011 to YTD 2017 11
Charles River Laboratories International Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
WIL Research Acquires Pharma Services Business Of Ricerca Biosciences 16
Inscopix Enters into Partnership with Brains On-Line 18
Nimbus Therapeutics Enters into Agreement with Charles River Laboratories International 19
Charles River Laboratories International Expands its Agreement with Chiesi Farmaceutici 20
Charles River Laboratories International Extends Agreement with Genentech 21
Charles River Labs Enters into Agreement with Tri-Institutional Therapeutics Discovery Institute 22
Moderna Therapeutics Enters into Agreement with Charles River Labs 23
Charles River Labs Enters into Agreement with BioMotiv 24
Eisai Extends Research Agreement with Charles River Labs 25
Charles River Labs Expands its Agreement with Michael J. Fox Foundation for Parkinson’s Research 26
Charles River Labs Enters into Agreement with Antabio 27
Charles River Labs Enters into Agreement with Pcovery 28
Charles River Labs Enters into Agreement with British Columbia Cancer Agency 29
Charles River Lab Extends Co-Development Agreement with CHDI Foundation 30
BioFocus Enters Into Drug Discovery Agreement With Boehringer Ingelheim 31
BioFocus Extends Agreement With Michael J. Fox Foundation For Parkinson's Disease 32
Applied StemCell Enters Into Distribution Agreement With Charles River Labs For Genetically Modified Targatt Mouse 33
BioFocus Enters Into Agreement With ChanTest 34
Charles River Labs Expands its Agreement with AstraZeneca 35
Ono Pharma Enters Into Discovery Agreement With BioFocus For CNS Drugs 36
Activiomics Enters Into Drug Discovery Agreement With BioFocus 37
Ono Pharma Enters Into Drug Discovery Agreement With BioFocus 38
Almirall Enters Into Integrated Drug Discovery Collaboration With BioFocus 39
Protagen Enters Into Co-Marketing Agreement With Charles River Labs 40
BioFocus Enters Into Co-Marketing Agreement With InterMed Discovery 41
BioFocus Enters Into Agreement With Michael J. Fox Foundation For Parkinson's Disease 42
BioFocus Extends Its Collaboration With Usher III Initiative 43
BioFocus Enters Into Co-Development Agreement With Astellas Pharma 44
BioFocus Enters Into An Agreement With Almac Group 45
ChanTest Corporation Enters Into Co-Marketing Agreement With Molecular Devices 46
Charles River Labs Enters Into Distribution Agreement With Pfizer 47
Ono Pharma Enters Into Co-Development Agreement With BioFocus 48
EMD Millipore Enters Into Licensing Agreement With Charles River Labs For TrueSpike Technology 49
Charles River Labs to Invest USD10 Million in BioMotiv 50
Charles River Labs International Sells Preclinical Assets 51
ShangPharma Acquires Shanghai In-vivo Drug Research Facility From Charles River Labs 52
Charles River Laboratories Acquires Brains On-Line 53
Quotient Clinical Acquires QS Pharma from Charles River Labs 54
Charles River Laboratories Acquires Agilux Laboratories for USD64.9 Million 55
Charles River Labs Acquires Blue Stream Labs 56
Charles River Laboratories Acquires WIL Research for USD604.8 Million 57
Charles River Labs Acquires Oncotest 59
Charles River Labs Acquires ChanTest from Ampersand Capital for USD59.2 Million 60
Charles River Labs Completes Acquisition Of BioFocus And Argenta Discovery From Galapagos For USD191.8 Million 61
Charles River Labs Acquires Brass 63
Charles River Labs Completes Acquisition Of 75% Stake In Vital River Labs For US$27 Million 64
Charles River Plans Sale Of The Company 65
Charles River Laboratories International Inc, Key Competitors 66
Charles River Laboratories International Inc, Key Employees 67
Charles River Laboratories International Inc, Subsidiaries 69

★海外企業調査レポート[Charles River Laboratories International Inc (CRL)-製薬・医療分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Curtiss-Wright Corp (CW)：石油・ガス：M&Aディール及び事業提携情報
    Summary Curtiss-Wright Corp (Curtiss-Wright) is a manufacturing and service company. It designs, manufactures, and overhauls precision components and provides highly engineered critical function products. The company also provides support services for critical applications. Curtiss-Wright serves cus …
  • Mears Group PLC (MER)：企業の財務・戦略的SWOT分析
    Summary Mears Group PLC (Mears) is a housing and social care provider. The company offers repairs, rapid response and planned maintenance services for a portfolio of social homes. It provides housing services such as new homes, energy services, housing management, home improvement, branches, planned …
  • Direct Energy Marketing Ltd：企業の戦略的SWOT分析
    Direct Energy Marketing Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • Eguana Technologies Inc (EGT)：企業の財務・戦略的SWOT分析
    Eguana Technologies Inc (EGT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Osprey Medical Inc (OSP)-医療機器分野：企業M&A・提携分析
    Summary Osprey Medical Inc (Osprey Medical) is a medical device company that designs, develops, and manufacturers proprietary devices and monitoring systems. The company provides contrast removal system, which is designed to provide cardiologists with an advanced level of CIN protection in high risk …
  • Symbiotec Pharmalab Ltd-製薬・医療分野：企業M&A・提携分析
    Summary Symbiotec Pharmalab Ltd (Symbiotec) is a medical laboratory that manufactures active pharmaceutical ingredients. The laboratory develops, produces and markets research-based cortico steroids and steroid-hormone APIs. Its cortico-steroids APIs include clobetasol propionate, betamethasone dipr …
  • FibroStatin SL：製薬・医療：M&Aディール及び事業提携情報
    Summary FibroStatin SL (FibroStatin) is a drug development company that focuses on the development of treatment candidates for drug resistant lung cancer and idiopathic pulmonary fibrosis. The company’s pipeline products include T12/FST12 for NSCLC, GPBP-Mab/FSM26 for idiopathic pulmonary fibrosis a …
  • Society for Worldwide Interbank Financial Telecommunication：企業の戦略的SWOT分析
    Society for Worldwide Interbank Financial Telecommunication - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, k …
  • The Boston Consulting Group：企業の戦略・SWOT・財務情報
    The Boston Consulting Group - Strategy, SWOT and Corporate Finance Report Summary The Boston Consulting Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • BNY Mellon Wealth Management：企業の戦略・SWOT・財務情報
    BNY Mellon Wealth Management - Strategy, SWOT and Corporate Finance Report Summary BNY Mellon Wealth Management - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • AMC Entertainment Holdings, Inc.：企業のM&A・事業提携・投資動向
    AMC Entertainment Holdings, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's AMC Entertainment Holdings, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on merge …
  • Mega Uranium Ltd (MGA)：企業の財務・戦略的SWOT分析
    Mega Uranium Ltd (MGA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • DHL Supply Chain：企業の戦略的SWOT分析
    DHL Supply Chain - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Prologis, Inc.：企業の戦略・SWOT・財務情報
    Prologis, Inc. - Strategy, SWOT and Corporate Finance Report Summary Prologis, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Stolt-Nielsen Ltd (SNI)-石油・ガス分野：企業M&A・提携分析
    Summary Stolt-Nielsen Ltd (Stolt-Nielsen) formerly Stolt-Nielsen S.A., is an integrated global transportation company, which provides bulk-liquid transportation, storage and distribution services. The company services include transportation of liquefied petroleum gas (LPG), terminal storage and dist …
  • Mead Johnson Nutrition Company：企業の戦略・SWOT・財務情報
    Mead Johnson Nutrition Company - Strategy, SWOT and Corporate Finance Report Summary Mead Johnson Nutrition Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Compass Minerals International Inc (CMP)：企業の財務・戦略的SWOT分析
    Compass Minerals International Inc (CMP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • JK Paper Ltd.：企業の戦略・SWOT・財務情報
    JK Paper Ltd. - Strategy, SWOT and Corporate Finance Report Summary JK Paper Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Tuesday Morning Corporation：企業の戦略・SWOT・財務情報
    Tuesday Morning Corporation - Strategy, SWOT and Corporate Finance Report Summary Tuesday Morning Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Berkshire Hathaway Energy Co-エネルギー分野：企業M&A・提携分析
    Summary Berkshire Hathaway Energy Company (BHE), a subsidiary of Berkshire Hathaway Inc., generates, transmits, stores, distributes, and supplies electricity; and procures, transports, distributes and sells natural gas through its subsidiaries. It generates power through diversified energy sources s …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆